Information Provided By:
Fly News Breaks for March 11, 2015
SNY, AMGN, REGN, PFE
Mar 11, 2015 | 07:31 EDT
Deutsche Bank believes the market for PCSK9 inhibitors, which the firm says lower "bad" cholesterol to a greater degree than statins alone, can top $22B by 2022 in the U.S. alone. Deutsche says that while Sanofi (SNY) and Regeneron's (REGN) Praluent as well as Amgen's (AMGN) Repatha have a head start on Pfizer's (PFE) bococizumab, the market opportunity is large enough to support multiple products. The firm raised its price target for Pfizer shares to $38 from $37 and keeps a Buy rating on the name. It also has Buy ratings on Amgen and Regeneron.
News For PFE;REGN;AMGN;SNY From the Last 2 Days
SNY
Apr 22, 2024 | 12:15 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
SNY
SNY
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.